Show simple item record

dc.contributor.authorSandvik, Reidun Karin Norheim Myhre
dc.contributor.authorSelbæk, Geir
dc.contributor.authorBergh, Sverre
dc.contributor.authorAarsland, Dag
dc.contributor.authorHusebø, Bettina
dc.date.accessioned2018-09-20T12:07:07Z
dc.date.available2018-09-20T12:07:07Z
dc.date.created2016-06-23T10:35:18Z
dc.date.issued2016-09
dc.identifier.citationJournal of the American Medical Directors Association. 2016, 17 (9), 821-827.nb_NO
dc.identifier.issn1525-8610
dc.identifier.urihttp://hdl.handle.net/11250/2563668
dc.description.abstractOBJECTIVES: To investigate whether it is possible to determine signs of imminent dying and change in pain and symptom intensity during pharmacological treatment in nursing home patients, from day perceived as dying and to day of death. DESIGN: Prospective, longitudinal trajectory trial. SETTING: Forty-seven nursing homes within 35 municipalities of Norway. PARTICIPANTS: A total of 691 nursing home patients were followed during the first year after admission and 152 were assessed carefully in their last days of life. MEASUREMENTS: Time between admission and day of death, and symptom severity by Edmonton symptom assessment system (ESAS), pain (mobilization-observation-behavior-intensity-dementia-2), level of dementia (clinical dementia rating scale), physical function (Karnofsky performance scale), and activities of daily living (physical self-maintenance scale). RESULTS: Twenty-five percent died during the first year after admission. Increased fatigue (logistic regression, odds ratio [OR] 1.8, P = .009) and poor appetite (OR 1.2, P = .005) were significantly associated with being able to identify the day a person was imminently dying, which was possible in 61% of the dying (n = 82). On that day, the administration of opioids, midazolam, and anticholinergics increased significantly (P < .001), and was associated with amelioration of symptoms, such as pain (mixed-models linear regression, 60% vs 46%, P < .001), anxiety (44% vs 31%, P < .001), and depression (33% vs 15%, P < .001). However, most symptoms were still prevalent at day of death, and moderate to severe dyspnea and death rattle increased from 44% to 53% (P = .040) and 8% to 19% (P < .001), respectively. Respiratory symptoms were not associated with opioids or anticholinergics. CONCLUSION: Pharmacological treatment ameliorated distressing symptoms in dying nursing home patients; however, most symptoms, including pain and dyspnea, were still common at day of death. Results emphasize critical needs for better implementation of guidelines and staff education. TRIAL REGISTRATION: ClinicalTrials.govNCT01920100.nb_NO
dc.language.isoengnb_NO
dc.publisherElseviernb_NO
dc.rightsNavngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/deed.no*
dc.subjectImminent dying; dementia; end-of-life care; nursing home medicine; palliative care; symptom managementnb_NO
dc.titleSigns of imminent dying and change in symptom intensity during pharmacological treatment in dying nursing home patients: a prospective trajectory studynb_NO
dc.title.alternativeSigns of imminent dying and change in symptom intensity during pharmacological treatment in dying nursing home patients: a prospective trajectory studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.rights.holder© 2016 AMDA The Society for Post-Acute and Long-Term Care Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).nb_NO
dc.source.pagenumber821-827nb_NO
dc.source.volume17nb_NO
dc.source.journalJournal of the American Medical Directors Associationnb_NO
dc.source.issue9nb_NO
dc.identifier.doi10.1016/j.jamda.2016.05.006
dc.identifier.cristin1363579
cristin.unitcode1991,9,1,0
cristin.unitnameAvd Alderspsykiatri
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal